Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences)(Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences))

概要

基本信息

药物类型

预防性疫苗

别名

GPO Avian Flu Vaccine、Influenza A virus vaccine H5N2 intranasal、Intranasal H5N2 vaccine

+ [4]

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

流感病毒感染

非在研适应症-

原研机构

Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences

在研机构

Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences

非在研机构-

最高研发阶段批准上市

首次获批日期

俄罗斯 (2012-11-28),

流感病毒感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的临床试验

NCT02153671 / Completed临床2期IIT

Immunogenicity of OrniFlu® Inactivated Influenza Vaccine in Subjects Previously Immunized With Live Attenuated H5N2 Influenza Vaccine and in Non-vaccinated Subjects

This study is designed to assess whether a live attenuated Influenza vaccine (LAIV) can induce a long-lasting immune memory by comparing the immunologic response to two doses of the OrniFlu® inactivated vaccine given to subjects previously primed with LAIV and subjects who did not received LAIV.

开始日期2014-05-01

申办/合作机构

Program for Appropriate Technology in Health

[+2]

NCT01982331 / Completed临床1期IIT

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/California/66/395 (H2N2)Influenza Vaccine

This is a phase I study to evaluate the safety of a vaccine to protect against influenza viruses of the H2N2 subtype. A total of 40 adults will be enrolled and receive two doses of vaccine or placebo one month apart.

开始日期2013-10-01

申办/合作机构

Program for Appropriate Technology in Health

[+2]

NCT01719783 / Completed临床1期IIT

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine

To evaluate the safety profile of two intranasal doses of LAIV A/17/turkey/Turkey/05/133 (H5N2) in healthy adults.

开始日期2012-09-01

申办/合作机构

Program for Appropriate Technology in Health

[+2]

100 项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的临床结果

登录后查看更多信息

100 项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的转化医学

登录后查看更多信息

100 项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的专利（医药）

登录后查看更多信息

77

项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的文献（医药）

2024-10-01·Vaccine: X

Vaccine optimization for highly pathogenic avian influenza: Assessment of antibody responses and protection for virus-like particle vaccines in chickens

Article

作者: Lin, Yi-Te ; Yang, Chin-Rur ; Wang, Pei-Ru ; Hsiao, Pei-Wen ; Yang, Yu-Chih ; Chen, Po-Ling ; Liang, Shu-Mei ; Ku, Chia-Chi ; Lin, Cheng-Yu ; Lee, Min-Shi

BackgroundRecent outbreaks of clade 2.3.4.4b highly pathogenic avian influenza (HPAI) H5N1 viruses in regions previously less affected since 2020 have raised global concerns. Implementing mass immunization or ring vaccination in poultry should be a countermeasure ready to contain disease outbreaks. This study focuses on developing a recombinant H5N2 vaccine based on virus-like particles (VLPs) against clade 2.3.4.4c, the predominant HPAI subclade in Taiwan since its emergence, leading to a large outbreak in 2015.MethodsThe study aimed to confirm the effectiveness of clade 2.3.4.4c H5N2 VLPs in protecting chickens and identify the best adjuvants for the VLP vaccine. We used Montanide 71VG-adjuvanted inactivated RG6 to establish the immunization protocol, followed by prime-boost H5N2-VLP immunizations. We compared adjuvants: 71VG, 71VG with VP3, and Alum with VP3. Serum samples were tested for antibodies against homologous vaccine antigens and cross-clade antigens by hemagglutination inhibition (HI) assays. Finally, we evaluated the protective efficacy by lethally challenging immunized chickens with H5 viruses from clade 1 or 2.3.4.4c.ResultsPoultry adjuvant 71VG significantly enhanced antibody responses in chickens with inactivated RG6 compared to unadjuvanted inactivated virus. While increasing antigen dosage enhanced 71VG adjuvanted RG6-induced antibody titers, the vaccine displayed minimal cross-reactivity against locally circulating HPAI H5N2. In contrast, H5N2-VLP containing the HA protein of clade 2.3.4.4c, adjuvanted with (FMDV) VP3 in 71VG, significantly promoted HI antibody responses. All H5N2-VLP immunized chickens survived lethal challenges with the local clade 2.3.4.4c H5 strain.ConclusionThe study demonstrated the immunogenic potential of the VLP vaccine in chickens. Our findings offer insights for optimizing VLP vaccines, allowing the incorporation of the HA of currently circulating H5 viruses to effectively mitigate the impact of the rapidly evolving clade 2.3.4.4 H5 outbreaks.

2022-12-01·Animal Diseases

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs

Article

作者: Artiaga, Bianca L ; Morozov, Igor ; Indran, Sabarish V ; Henningson, Jamie ; Ransburgh, Russell ; Balaraman, Velmurugan ; De Carvalho Madrid, Darling Melany ; Gu, Weihong ; Driver, John P ; Richt, Jürgen A ; Kwon, Taeyong ; Ma, Wenjun

AbstractNatural killer T (NKT) cells activated with the glycolipid ligand α-galactosylceramide (α-GalCer) stimulate a wide variety of immune cells that enhance vaccine-mediated immune responses. Several studies have used this approach to adjuvant inactivated and subunit influenza A virus (IAV) vaccines, including to enhance cross-protective influenza immunity. However, less is known about whether α-GalCer can enhance live attenuated influenza virus (LAIV) vaccines, which usually induce superior heterologous and heterosubtypic immunity compared to non-replicating influenza vaccines. The current study used the swine influenza challenge model to assess whether α-GalCer can enhance cross-protective immune responses elicited by a recombinant H3N2 LAIV vaccine (TX98ΔNS1) encoding a truncated NS1 protein. In one study, weaning pigs were administered the H3N2 TX98ΔNS1 LAIV vaccine with 0, 10, 50, and 100 μg/kg doses of α-GalCer, and subsequently challenged with a heterologous H3N2 virus. All treatment groups were protected from infection. However, the addition of α-GalCer appeared to suppress nasal shedding of the LAIV vaccine. In another experiment, pigs vaccinated with the H3N2 LAIV, with or without 50 μg/kg of α-GalCer, were challenged with the heterosubtypic pandemic H1N1 virus. Pigs vaccinated with the LAIV alone generated cross-reactive humoral and cellular responses which blocked virus replication in the airways, and significantly decreased virus shedding. On the other hand, combining the vaccine with α-GalCer reduced cross-protective cellular and antibody responses, and resulted in higher virus titers in respiratory tissues. These findings suggest that: (i) high doses of α-GalCer impair the replication and nasal shedding of the LAIV vaccine; and (ii) α-GalCer might interfere with heterosubtypic cross-protective immune responses. This research raise concerns that should be considered before trying to use NKT cell agonists as a possible adjuvant approach for LAIV vaccines.

2022-11-01·Vaccine

Reverse genetics based H5N2 vaccine provides clinical protection against H5N1, H5N8 and H9N2 avian influenza infection in chickens

Article

作者: Bhatia, Sandeep ; Kalaiyarasu, Semmannan ; Bhandari, Nisha ; Panickan, Sivasankar ; Sood, Richa ; Tripathi, Meghna ; Pateriya, Atul Kumar ; Bhat, Sushant

The current study aimed to develop broadly protective vaccines for avian influenza. In an earlier study, HA stalk (universal flu vaccine) was found to be broadly protective against different subtypes of influenza virus in mice. Hence, we were interested to know its breadth of protective efficacy either alone or combined with inactivated rgH5N2 (clade 2.3.2.1a) vaccine against challenge viruses of homologous H5N1, heterologous H5N8 (clade 2.3.4.4) and heterosubtypic H9N2 virus in specific pathogen-free chickens. The rgH5N2 vaccine alone or in combination with HA stalk elicited sufficient pre-challenge immunity in the form of haemagglutination inhibiting (HI) antibodies and neutralizing antibodies (MNT) against H5N1, H5N8, and H9N2 in chickens. The rgH5N2 vaccine alone or in combination with HA stalk also attenuated the shedding of H5N1, H5N8 and H9N2 in chickens and protected against the lethal challenge of H5N1 or H5N8. In contrast, all HA stalk immunised chickens died upon H5N1 or H5N8 challenge and H9N2 challenged chickens survived. Our study suggests that the rgH5N2 vaccine can provide clinical protection against H5N1, H5N8 and can attenuate the viral shedding of H9N2 in chickens.

100 项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	俄罗斯	Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences	2012-11-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01982331 (CTgov)	临床1期	流感病毒感染	38	LAIV H2N2 (LAIV H2N2 Vaccine)	憲繭糧齋構憲觸淵糧壓(窪襯製廠襯齋膚憲壓繭) = 鹹顧網窪繭憲鹹衊鏇膚餘糧齋鏇襯遞淵簾築繭 (構製齋簾觸鏇鑰淵鑰餘, 壓憲餘廠範齋遞糧齋鬱 ~ 膚蓋淵艱積簾簾餘憲夢) 更多	-	2019-02-06
NCT01982331 (CTgov)	临床1期	流感病毒感染	38	Placebo (Placebo)	憲繭糧齋構憲觸淵糧壓(窪襯製廠襯齋膚憲壓繭) = 鹽築積糧觸願艱憲襯膚餘糧齋鏇襯遞淵簾築繭 (構製齋簾觸鏇鑰淵鑰餘, 鬱廠壓蓋壓蓋願繭廠鹹 ~ 夢齋憲膚糧鏇餘餘膚膚) 更多	-	2019-02-06
IAS2004	N/A	HIV感染	-	GPO-VIR	(鑰網夢獵蓋積鏇鬱積構) = Adverse events (rash, hepatitis, and nausea/vomiting) were found in 13 (14%) patients. 壓鬱衊遞願窪顧衊淵願 (膚願鹹製壓鏇壓夢積鑰 )	-	2004-01-01